New startup ideas · Health and bio · Healthcare and bio

startup idea

Astrid

Monthly at-home blood cartridge that learns your baseline, not the population's.

Astrid ships a reusable reader and a monthly single-use microsampling cartridge that runs a panel of metabolic, inflammatory and hormonal markers from a few drops of blood at home, then charges a consumer subscription for the software that tracks how far each result has drifted from that person's own history and from matched members of the same age, sex and physiology.

Software subscription
Consumer
$100B+ market
Creates a new category
Global from day one

3/5

venture judge

similar startups, last 2 years (3 all-time)

97%

of 4 nearest real companies still alive

yes

8 matching federal grants and programs

Direction supported by government programs and grants

Test it before you build it

$1,650 · 4 weeks · 30 prospects

Prove that people already paying for quarterly blood panels will put down $100 reservations and buy a $29 baseline-drift report today, for $1,650 in four weeks.

Riskiest assumption · People who already pay $400+ a year for quarterly private panels will hand over money now, both a $100 reservation for hardware 18 months out and $29 for baseline software today, rather than treating personal-baseline tracking as a nice idea they keep doing in a spreadsheet.

1Focus group: who and where

US consumers, mostly 30-55, who already pay $400-1,500 a year out of pocket for quarterly panels through Function Health, InsideTracker, Marek Health or a local direct-to-consumer lab, and who track results in a spreadsheet because no service reads their history

where to find 30 · r/Biohackers and r/QuantifiedSelf on Reddit; the Quantified Self community forum at forum.quantifiedself.com; attendee and speaker circles of Dave Asprey's Biohacking Conference; review threads and community discussions around Function Health and InsideTracker where users compare panel prices

2Sell first, build later

Founding membership: a reusable reader and 12 monthly cartridges priced at cost, plus software that scores every result against your own history and a matched cohort; first 500 readers target shipping in 18 months, and a manual baseline-drift report from your existing lab PDFs starts the day you reserve

the ask · $100 refundable reservation now; $199 per year for the software at launch, locked for founding members; $29 per manual drift report today

a real yes · A real yes is $100 charged at checkout or $29 paid for a drift report. Not a yes: waitlist emails, upvotes, 'I would 100 percent buy this', or interviewees who praise the idea and reserve nothing

3Small experiments

The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.

1. Priced reservation smoke test
$750 · 14 days
Put up a one-page site: monthly at-home cartridge, panel list, $199 per year software with reader and cartridges at cost, and a $100 fully refundable reservation checkout with an honest 'first 500 readers target shipping in 18 months' line. Drive traffic with Reddit ads targeted at r/Biohackers and r/QuantifiedSelf.
keep going if · 10 paid $100 reservations from roughly 1,200 visitors, a rate near 1 percent of qualified traffic
2. Twenty panel-buyer interviews
$100 · 14 days
Recruit 20 current quarterly-panel buyers from the subreddits and the Quantified Self forum with a plain 'I'll trade you 30 minutes on what your panels cost you' post. Ask what they pay now, show the priced page live on the call, and make the reservation ask directly.
keep going if · 12 of 20 pay $400+ per year today, and 5 of 20 reserve on or within 48 hours of the call
3. Manual drift report sales
$200 · 18 days
Offer the software's core value with no hardware: they upload their last 3-8 panel PDFs, we hand-build a $29 report showing each marker's drift against their own history, delivered in 72 hours. Offer it to every interviewee and in one follow-up post; founders build each report in a spreadsheet.
keep going if · 10 of 30 people offered buy the $29 report, and 5 of the first 10 buyers opt into a second monthly report
4. Creator channel price check
$600 · 10 days
Pay one mid-size longevity or biohacking YouTube creator for a single dedicated mention linking to the reservation page with a tracked code. This tests whether the eventual acquisition channel produces reservations at a sane cost, not just subreddit natives.
keep going if · 8 or more reservations from the creator link, an effective cost under $75 per reservation

4Collect a deposit up front

Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.

$100

per prospect, refundable

how · A $100 refundable reservation taken by card at the landing-page checkout, the standard instrument for consumer hardware sold before it exists; the buyer sees the ship-date estimate and refund rule on the checkout page before paying set up: Stripe Checkout ↗

what it reserves · A reader in the first 500-unit cohort, the $199 per year founding price locked for life, and immediate access to the monthly manual drift report

refund · Refundable in full, self-serve, any time before the reader ships

target · 25 paid reservations within 30 days across ads, interviews and the creator test

before taking money · Sell only general-wellness tracking and hardware reservations for now: no diagnostic claims, no interpreted disease risk, and no marketed panel results before counsel reviews FDA device and CLIA boundaries.

Go: build it if

25+ reservations at a blended cost under $70 each, 10+ drift-report sales with half of buyers taking a second month, and 12+ of 20 interviewees confirming $400+ current annual panel spend

Kill: stop if

Fewer than 8 reservations from 1,500+ qualified visitors and 20 interviews, or fewer than 4 of 30 buying the $29 report, which means even the software layer alone is a vitamin

5 Scripts to run itoutreach message, landing copy, deposit terms · click to open

outreach message

You're paying a few hundred dollars a quarter for panels, and I'd bet the results sit in PDFs that nothing compares against your own history. I'm building a monthly at-home cartridge that scores every marker against your personal baseline, and before I build hardware I'm talking to 20 people who actually buy panels today. Can I get 30 minutes this week? I'll walk through your last few results and show you exactly what drift-versus-baseline looks like on your own numbers.

landing page

Monthly blood panel at home, scored against your own baseline. $100 refundable reservation locks founding pricing: $199 a year, hardware at cost, drift reports from your existing labs starting now. Reserve your reader.

deposit terms

Your $100 reservation holds a reader in the first 500-unit cohort and locks the $199 per year founding price for life; the first cohort targets shipping in 18 months. It is fully refundable, self-serve, any time before your reader ships. Your manual baseline-drift reports from existing lab results start within 72 hours of reserving.

Would you run this test?

One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.

Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.

Scorecard

One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.

Idea Score, 0-100 · raw 40.7 x 1.61

Open

competition: more crowded than 6% of ideas · headwind x0.97

+3.0

government priorities, secondary (21 matching grants)

Trend

Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.

Entrants 2025-26 vs 2023-24 (similar companies)23
Rounds announced 2025+ in the sector69
Sector direction (live batch)100
2026 trend analyst0

Demand

Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.

YC asks for it (current RFS: idea / sector)30
Someone already pays (similar companies, recent / all-time)25
Operator judge: real pain0

100x potential

Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.

Venture judge50
Market size axis100
Moat axis100
Neighbours still alive1
Technologist judge100

Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were monthly, at-home, blood, cartridge, learns, baseline, not, population.

The idea in full

What: Astrid ships a reusable reader and a monthly single-use microsampling cartridge that runs a panel of metabolic, inflammatory and hormonal markers from a few drops of blood at home, then charges a consumer subscription for the software that tracks how far each result has drifted from that person's own history and from matched members of the same age, sex and physiology. Hardware and consumables are priced at cost so the recurring software fee is the business. Getting there means three years of assay development, manufacturing scale-up and regulatory work before the first paid subscription.
Why now: Strand AI (yc W26) is building multimodal foundation models to predict uncollected patient biology and Carevision Inc. (500global) sells 60-second cardiometabolic screening, both of which need repeated real measurement to be worth anything; the graveyard entry Layers (2025), a 30-minute appointment to measure everything in your body, shows the one-shot clinic version does not survive.
Wedge: first customer and entry point: The existing longevity self-quantifier who already pays for quarterly private blood panels: one cartridge, one panel, sold direct at a lower annual price than two clinic draws.
Path to 100x: Consumer health and longevity spending is well past $100B globally and none of it is a recurring measurement subscription with a personal baseline. The network effect is real on the consumption side: every additional member sharpens the matched-cohort comparison that makes an individual result interpretable, so a member switching to a competitor loses their peer set as well as their history, and families join together because inherited baselines compare.
Ceiling: If regulators require each interpreted marker to clear diagnostic claims, Astrid narrows to a wellness gadget with high churn after the novelty year.
Closest real companies, as the generator saw them: Illume Labs is a 24/7 longevity companion built on data the user does not collect, and Gutgutgoose personalises one intervention; Astrid owns the measurement stream itself, which is the input both of them lack. Layers proved the clinic-visit version dies.
Main risk: At-home microsampling cannot hold clinical-grade precision on enough markers, and drift detection drowns in assay noise.

Five judges

Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).

Venture investor
3/5
Real cohort network effect and $100B+ consumer spend, but three years of assay and manufacturing work before a single paid subscription.
Bootstrapper
1/5
Three years of assay development and manufacturing scale-up before one subscription, on consumer buyers who churn after the novelty year.
Operator
1/5
A consumer longevity subscription priced against quarterly private panels is a vitamin with three years of assay work before the first euro.
Technologist
5/5
Reusable reader plus single-use microsampling cartridge holding clinical precision on metabolic and hormonal markers is three years of assay and manufacturing depth.
Risk
2/5
Three years of assay and manufacturing spend before a euro of subscription, with diagnostic claim rules able to reduce it to a wellness gadget.
trends
1/5
Why-now is one W26 company and a dead clinic startup; at-home blood panels plus three years of assay R&D had no 2025-2026 unlock.

Similar startups in the directory

Companies whose pitch matches most of the idea's terms (monthly, at-home, blood, cartridge, learns, baseline, not, population): 3 all-time, 0 from the last two years. Same matching as Idea Check.

Alltruistsyc W21 · 2021 · Consumersite down
Kid-friendly, at-home volunteer projects in a box, delivered bimonthly
Qvinyc W16 · 2016 · Healthcare and bioalive
Empowering women. Period.
Stata DXplugandplay · Healthcare and bioalive
Stata DX is a developer of a disease management eRapid technology designed to implement custom biomarker panels for clinical studies.

Run this as an Idea Check →

The generator's reference companies

Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.

Public money in this direction

US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.

grants and programs matching the idea

1595

startup-relevant grants in Healthcare and bio

$854M

awarded in the sector, tracked

118

opportunities open now in the sector

A wearable device for at-home sleep studies that merges comfort with clinical-grade insightsawardhigh relevance
NIH / NHLBI · SBIR phase I · $418K · posted 2026-09-01
Flourish All: Women's Integrated Stress Reduction for Alzheimer's Risk Prevention Using Digital Tools and Biomarker Monitoringawardhigh relevance
NIH / NIA · SBIR phase II · $474K · posted 2025-09-20
Novel Myofunctional Nipple to Prevent Obstructive Sleep Apnea in Infantsawardhigh relevance
NIH / NHLBI · SBIR phase I · $317K · posted 2025-09-15
Advancing Site-Selective Multi-Payload HER2-Targeted Conjugates to Overcome Resistance and Boost Survival in Breast and Gastric Cancersawardhigh relevance
NIH / NCI · SBIR phase II · $1M · posted 2026-09-21
A Smart Remote Monitoring System for Cardiometabolic Management in Patients with Alzheimer's and Related Dementiaawardhigh relevance
NIH / NIA · SBIR phase I · $500K · posted 2026-09-18
Alphavirus vector-mediated expression of a connexin43 mimetic peptide in glioblastoma therapyawardhigh relevance
NIH / NCI · STTR phase I · $400K · posted 2026-09-18
A novel AI platform to detect cellular senescence and measure biological age using biofluidsawardhigh relevance
NIH / NIA · SBIR phase I · $397K · posted 2026-09-16
A Phase 2 Study of SX-682 in Combination with Nivolumab and Relatlimab in Melanoma Patientsawardhigh relevance
NIH / NCI · SBIR phase II · $407K · posted 2026-09-14

All public money by sector →

Market signal

What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.

Healthcare and bio · 135 → 121 → 224 → 173 → 127 new companies 2022 → 2026 · 91% aliveYC F26 live: 2 in this cluster, 2% of the batch (was 6% in S26)Since February, of 442 YC companies here: 6 acquired, 6 shut down, 45 rewrote their pitch

Healthcare and bio: companies, trend and grants →

Design attributes

The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.

Buyer: Consumer
Business model: Software subscription
Path to 100x: Creates a new category
Market size: $100B+ market
Capital intensity: Capital-heavy (hardware, bio, infra)
Speed to revenue: R&D first, revenue after 3 years
Technical depth: Real engineering
Go-to-market: Self-serve
Moat: Network effects
Geography: Global from day one
Regulation: Some regulation
Vibe: Hot space